Literature DB >> 25973346

INVESTIGATING THE EFFICACY OF CLINICAL TRIAL MONITORING STRATEGIES: Design and Implementation of the Cluster Randomized START Monitoring Substudy.

Katherine Huppler Hullsiek1, Jonathan M Kagan2, Nicole Engen1, Jesper Grarup3, Fleur Hudson4, Eileen T Denning1, Catherine Carey5, David Courtney-Rodgers5, Elizabeth B Finley6, Per O Jansson3, Mary T Pearson3, Dwight E Peavy7, Waldo H Belloso8.   

Abstract

BACKGROUND: Trial monitoring protects participant safety and study integrity. While monitors commonly go on-site to verify source data, there is little evidence that this practice is efficient or effective. An ongoing international HIV treatment trial (START) provides an opportunity to explore the usefulness of different monitoring approaches.
METHODS: All START sites are centrally monitored and required to follow a local monitoring plan requiring specific quality assurance activities. Additionally, sites were randomized (1:1) to receive, or not receive, annual on-site monitoring. The study will determine if on-site monitoring increases the identification of major protocol deviations (eligibility or consent violations, improper study drug use, primary or serious event underreporting, data alteration or fraud).
RESULTS: The START study completed enrollment in December 2013, with planned follow-up through December 2016. The monitoring study is ongoing at 196 sites in 34 countries. Results are expected when the START study concludes in December 2016.

Entities:  

Keywords:  Data monitoring; centralized monitoring; clinical trials; on-site monitoring; quality assurance

Year:  2015        PMID: 25973346      PMCID: PMC4426264          DOI: 10.1177/2168479014555912

Source DB:  PubMed          Journal:  Ther Innov Regul Sci        ISSN: 2168-4790            Impact factor:   1.778


  25 in total

1.  The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials.

Authors:  M Buyse; S L George; S Evans; N L Geller; J Ranstam; B Scherrer; E Lesaffre; G Murray; L Edler; J Hutton; T Colton; P Lachenbruch; B L Verma
Journal:  Stat Med       Date:  1999-12-30       Impact factor: 2.373

2.  CONSORT statement: extension to cluster randomised trials.

Authors:  Marion K Campbell; Diana R Elbourne; Douglas G Altman
Journal:  BMJ       Date:  2004-03-20

3.  Ethical and scientific implications of the globalization of clinical research.

Authors:  Seth W Glickman; John G McHutchison; Eric D Peterson; Charles B Cairns; Robert A Harrington; Robert M Califf; Kevin A Schulman
Journal:  N Engl J Med       Date:  2009-02-19       Impact factor: 91.245

4.  Impact of on-site initiation visits on patient recruitment and data quality in a randomized trial of adjuvant chemotherapy for breast cancer.

Authors:  J-L Liénard; E Quinaux; E Fabre-Guillevin; P Piedbois; A Jouhaud; G Decoster; M Buyse
Journal:  Clin Trials       Date:  2006       Impact factor: 2.486

5.  Reducing the costs of phase III cardiovascular clinical trials.

Authors:  Eric L Eisenstein; Philip W Lemons; Barbara E Tardiff; Kevin A Schulman; M King Jolly; Robert M Califf
Journal:  Am Heart J       Date:  2005-03       Impact factor: 4.749

Review 6.  Simple sample size calculation for cluster-randomized trials.

Authors:  R J Hayes; S Bennett
Journal:  Int J Epidemiol       Date:  1999-04       Impact factor: 7.196

7.  Sensible approaches for reducing clinical trial costs.

Authors:  Eric L Eisenstein; Rory Collins; Beena S Cracknell; Oscar Podesta; Elizabeth D Reid; Peter Sandercock; Yuriy Shakhov; Michael L Terrin; Mary Ann Sellers; Robert M Califf; Christopher B Granger; Rafael Diaz
Journal:  Clin Trials       Date:  2008       Impact factor: 2.486

8.  Ensuring trial validity by data quality assurance and diversification of monitoring methods.

Authors:  Colin Baigent; Frank E Harrell; Marc Buyse; Jonathan R Emberson; Douglas G Altman
Journal:  Clin Trials       Date:  2008       Impact factor: 2.486

9.  Risk analysis and risk adapted on-site monitoring in noncommercial clinical trials.

Authors:  Oana Brosteanu; Peggy Houben; Kristina Ihrig; Christian Ohmann; Ursula Paulus; Beate Pfistner; Gabriele Schwarz; Anke Strenge-Hesse; Ulrike Zettelmeyer
Journal:  Clin Trials       Date:  2009-11-06       Impact factor: 2.486

10.  Interleukin-2 therapy in patients with HIV infection.

Authors:  D Abrams; Y Lévy; M H Losso; A Babiker; G Collins; D A Cooper; J Darbyshire; S Emery; L Fox; F Gordin; H C Lane; J D Lundgren; R Mitsuyasu; J D Neaton; A Phillips; J P Routy; G Tambussi; D Wentworth
Journal:  N Engl J Med       Date:  2009-10-15       Impact factor: 91.245

View more
  7 in total

Review 1.  The impact of clinical trial monitoring approaches on data integrity and cost--a review of current literature.

Authors:  Rasmus Olsen; Asger Reinstrup Bihlet; Faidra Kalakou; Jeppe Ragnar Andersen
Journal:  Eur J Clin Pharmacol       Date:  2016-01-04       Impact factor: 2.953

2.  A randomized evaluation of on-site monitoring nested in a multinational randomized trial.

Authors:  Nicole Wyman Engen; Kathy Huppler Hullsiek; Waldo H Belloso; Elizabeth Finley; Fleur Hudson; Eileen Denning; Catherine Carey; Mary Pearson; Jonathan Kagan
Journal:  Clin Trials       Date:  2019-10-24       Impact factor: 2.486

3.  Impact of a targeted monitoring on data-quality and data-management workload of randomized controlled trials: A prospective comparative study.

Authors:  Claire Fougerou-Leurent; Bruno Laviolle; Christelle Tual; Valérie Visseiche; Aurélie Veislinger; Hélène Danjou; Amélie Martin; Valérie Turmel; Alain Renault; Eric Bellissant
Journal:  Br J Clin Pharmacol       Date:  2019-12-14       Impact factor: 4.335

4.  Exploring Data Quality Management within Clinical Trials.

Authors:  Lauren Houston; Yasmine Probst; Ping Yu; Allison Martin
Journal:  Appl Clin Inform       Date:  2018-01-31       Impact factor: 2.342

Review 5.  Monitoring strategies for clinical intervention studies.

Authors:  Katharina Klatte; Christiane Pauli-Magnus; Sharon B Love; Matthew R Sydes; Pascal Benkert; Nicole Bruni; Hannah Ewald; Patricia Arnaiz Jimenez; Marie Mi Bonde; Matthias Briel
Journal:  Cochrane Database Syst Rev       Date:  2021-12-08

6.  Risk-adapted monitoring is not inferior to extensive on-site monitoring: Results of the ADAMON cluster-randomised study.

Authors:  Oana Brosteanu; Gabriele Schwarz; Peggy Houben; Ursula Paulus; Anke Strenge-Hesse; Ulrike Zettelmeyer; Anja Schneider; Dirk Hasenclever
Journal:  Clin Trials       Date:  2017-08-08       Impact factor: 2.486

7.  Triggered or routine site monitoring visits for randomised controlled trials: results of TEMPER, a prospective, matched-pair study.

Authors:  Sally P Stenning; William J Cragg; Nicola Joffe; Carlos Diaz-Montana; Rahela Choudhury; Matthew R Sydes; Sarah Meredith
Journal:  Clin Trials       Date:  2018-08-22       Impact factor: 2.486

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.